The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. 2018

Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
a Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories , Hamilton , MT , USA.

The devastating Ebola virus (EBOV) epidemic in West Africa in 2013-2016 accelerated the progress of several vaccines and antivirals through clinical trials, including the replication-competent vesicular stomatitis virus-based vaccine expressing the EBOV glycoprotein (VSV-EBOV). Extensive preclinical testing in animal models demonstrated the prophylactic and post-exposure efficacy of this vaccine, identified the mechanism of protection, and suggested it was safe for human use. Based on these data, VSV-EBOV was extensively tested in phase 1-3 clinical trials in North America, Europe and Africa. Although some side effects of vaccination were observed, these clinical trials showed that the VSV-EBOV was safe and immunogenic in humans. Moreover, the data supported the use of VSV-EBOV as an emergency vaccine in individuals at risk for Ebola virus disease. In this review, we summarize the results of the extensive preclinical and clinical testing of the VSV-EBOV vaccine.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D046129 Ebola Vaccines Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER. Ebola Vaccine,Ebola Virus Vaccine,Ebola Virus Vaccines,Ebolavirus Vaccine,Ebolavirus Vaccines,Vaccine, Ebola,Vaccine, Ebola Virus,Vaccine, Ebolavirus,Vaccines, Ebola,Vaccines, Ebola Virus,Vaccines, Ebolavirus,Virus Vaccine, Ebola,Virus Vaccines, Ebola
D018116 Vesiculovirus A genus of the family RHABDOVIRIDAE that infects a wide range of vertebrates and invertebrates. The type species is VESICULAR STOMATITIS INDIANA VIRUS. Chandipura virus,Vesicular stomatitis Alagoas virus,Vesiculoviruses
D019142 Hemorrhagic Fever, Ebola A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS. Ebola Hemorrhagic Fever,Ebola Virus Disease,Ebolavirus Infection,Ebola Infection,Ebola Virus Infection,Ebolavirus Infections,Infection, Ebola,Infection, Ebola Virus,Infection, Ebolavirus,Infections, Ebolavirus,Virus Infection, Ebola

Related Publications

Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
January 2017, The New England journal of medicine,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
March 2016, The Journal of infectious diseases,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
January 2021, Drugs of today (Barcelona, Spain : 1998),
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
November 2008, PLoS pathogens,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
February 2015, Emerging infectious diseases,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
August 2021, Pathogens (Basel, Switzerland),
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
January 2015, JAMA,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
November 2011, The Journal of infectious diseases,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
November 2023, The Journal of infectious diseases,
Ellen Suder, and Wakako Furuyama, and Heinz Feldmann, and Andrea Marzi, and Emmie de Wit
November 2011, The Journal of infectious diseases,
Copied contents to your clipboard!